A blood test for depression?

July 22, 2010

Blood tests have been extremely important tools aiding doctors in making medical diagnoses and in guiding the treatment of many diseases. However, psychiatry is one area of medicine where there are few diagnostic blood tests.

New scientific fields may someday generate blood tests that can be used for these purposes. Some of the areas under increasingly intensive study are genetics, the study of variations in the genes (DNA) that can be extracted from , and genomics like proteomics, the measurement of the levels of specific proteins in the blood, and gene expression profiling, which measures the levels of RNA produced from DNA as an indication of the level of the "activity" of particular genes.

Using the latter approach, Dutch researchers evaluated blood gene expression profiles in healthy individuals and patients diagnosed with major , or MDD. They identified a set of seven genes in whole blood that was able to distinguish un-medicated MDD patients from healthy controls.

"This is a first, but major step in providing a molecular for depression," explained Dr. Sabine Spijker, corresponding author of this study. Although psychiatry already has specific criteria for diagnosing mental health disorders, this type of diagnosis would be unbiased and particularly valuable for those with whom it is more difficult to have a conversation. It may also eventually assist in reducing the stigma associated with mental health problems.

"It is far too early to be confident that gene expression profiling will lead us to diagnostic or prognostic tests for depression. However, the objective of this line of research is extremely important," cautions Dr. John Krystal, Editor of . "In the past, many types of tests have been explored as potential diagnostic markers, but they all have failed to have sufficient sensitivity and specificity to guide doctors in making psychiatric diagnoses or choosing between treatments. I look forward to seeing whether the patterns of gene expression profiling are replicable and diagnostically specific as multiple groups report their findings."

Most importantly, the authors hope that this study is a stepping stone for finding markers that might predict treatment outcome and recurrence.

More information: The article is "Stimulated Gene Expression Profiles as a Blood Marker of Major Depressive Disorder" by Sabine Spijker, et al. The article appears in Biological Psychiatry, Volume 68, Issue 2 (July 15, 2010)

Related Stories

Recommended for you

Abusive avatars help schizophrenics fight 'voices': study

November 24, 2017
"You're rubbish. You're rubbish. You're a waste of space." The computer avatar pulls no punches as it lays into the young woman, a schizophrenia sufferer, facing the screen.

Ten-month-old infants determine the value of a goal from how hard someone works to achieve it

November 23, 2017
Babies as young as 10 months can assess how much someone values a particular goal by observing how hard they are willing to work to achieve it, according to a new study from MIT and Harvard University.

Stress in pregnancy linked to changes in infant's nervous system, less smiling, less resilience

November 23, 2017
Maternal stress during the second trimester of pregnancy may influence the nervous system of the developing child, both before and after birth, and may have subtle effects on temperament, resulting in less smiling and engagement, ...

Domestic violence turns women off masculine men

November 23, 2017
Women who are afraid of violence within partnerships prefer more feminine men, according to new research carried out by scientists at the University of St Andrews.

Study finds infection and schizophrenia symptom link

November 22, 2017
If a mother's immune system is activated by infection during pregnancy, it could result in critical cognitive deficits linked to schizophrenia in her offspring, a University of Otago study has revealed.

Schizophrenia drug development may be 'de-risked' with new research tool

November 22, 2017
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) have identified biomarkers that can aid in the development of better treatments for schizophrenia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.